Understanding Primary Sclerosing Cholangitis: Symptoms & Management

Added:

Microbiome-Targeted Therapy and Oral Vancomycin in PSC Management

While mainstream hepatology guidelines maintain that there is currently no approved medical therapy to halt the progression of Primary Sclerosing Cholangitis (PSC)—limiting standard care to symptom management, surveillance, and eventual liver transplantation—an active alternative perspective focuses on the gut-liver axis. Proponents of this view advocate for microbiome-targeted interventions, most notably Oral Vancomycin Therapy (OVT). Particularly in pediatric patients and those with concurrent Inflammatory Bowel Disease (PSC-IBD), some clinical studies suggest OVT can normalize liver enzymes, resolve symptoms, and potentially arrest disease progression by altering the gut microbiota and reducing inflammatory pathways. Standard guidelines remain cautious, citing a lack of large-scale, randomized controlled trials and potential risks of antibiotic resistance. Nonetheless, this perspective challenges the conventional therapeutic nihilism surrounding PSC, suggesting that targeting the gut microbiome offers a viable disease-modifying strategy rather than relying solely on palliative care and biliary surveillance.

Anatomy and physiology of the hepatobiliary system, specifically the structure and function of the intrahepatic and extrahepatic bile ducts.
Basic understanding of liver function tests (LFTs), including alkaline phosphatase (ALP), bilirubin, and transaminases (ALT/AST).
Fundamental concepts of autoimmune and chronic inflammatory diseases, as PSC is an immune-mediated progressive disorder.
The clinical relationship between Inflammatory Bowel Disease (IBD), particularly Ulcerative Colitis, and hepatobiliary complications.
Advanced diagnostic imaging techniques for biliary diseases, such as Magnetic Resonance Cholangiopancreatography (MRCP) and Endoscopic Retrograde Cholangiopancreatography (ERCP).
Surveillance protocols for major complications of long-term PSC, including cholangiocarcinoma, gallbladder cancer, and colon cancer.
The evaluation process, indications, and outcomes for liver transplantation in patients with end-stage liver disease caused by PSC.
Current clinical trials, emerging pharmacotherapies (such as obeticholic acid or norUDCA), and the management of overlap syndromes like PSC-AIH.
890 views13likes1:27:04@PSCPartnersOriginal Release: 2022-05-09

Primary Sclerosing Cholangitis (PSC) is a chronic progressive liver disease characterized by inflammation and fibrosis of the bile ducts, causing bile reflux and liver damage; diagnosis relies on elevated alkaline phosphatase and gamma-glutamyl transferase levels indicating cholestatic injury, confirmed by magnetic resonance cholangiopancreatography (MRCP) showing characteristic bile duct strictures, with treatment focusing on managing symptoms like pruritus (itching) through medications such as ursodeoxycholic acid, cholestyramine, rifampin, and naltrexone, while monitoring for complications including cholangiocarcinoma, inflammatory bowel disease, vitamin deficiencies, and osteoporosis.